Company Overview
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.12.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +87.31% |
| 6 Months: | -5.62% |
| 3 Months: | -7.94% |
| 1 Month: | -13.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross1d ago
- RSI (14)41.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 30.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANNX Annexon, Inc. R2KR3KPHARMA | 4.87 | -4.06 | $797.91M | 0.00% | -92.11% | -87.65% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 57.41M | 51.73M | 57.02M | 50.26M | 46.05M |
| Operating Income | - | -8.22M | -9.07M | -12.46M | -12.24M | -15.59M | -26.20M | -31.37M | -35.68M | -35.43M | -37.41M | -36.07M | -41.24M | -37.69M | -34.78M | -28.57M | -33.58M | - | -57.41M | -51.73M | -57.02M | -50.26M | -46.05M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -56.69M | -51.11M | -56.47M | -49.72M | -45.40M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.36M | -49.16M | -54.92M | -48.26M | -44.14M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.65M | -9.40M | -10.19M | -12.34M | -12.24M | -15.64M | -26.06M | -31.29M | -35.60M | -35.37M | -37.14M | -35.05M | -38.68M | -35.19M | -32.48M | -25.18M | -29.61M | - | -54.36M | -49.16M | -54.92M | -48.26M | -44.14M |
| Diluted EPS | - | - | - | - | - | - | - | -0.82 | -0.93 | -0.92 | -0.96 | -0.51 | -0.52 | -0.47 | -0.43 | -0.21 | -0.23 | - | -0.37 | -0.34 | -0.37 | -0.28 | -0.23 |
| R&D Expense | - | 5.99M | 7.09M | 10.22M | 9.29M | 11.78M | 20.70M | 24.57M | 27.58M | 27.00M | 29.11M | 27.86M | 32.34M | 30.25M | 27.89M | 20.96M | 25.03M | 30.11M | 48.18M | 44.16M | 49.70M | - | 35.79M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 145.60M | 143.72M | 154.07M | 216.41M |
| Operating Income | -32.52M | -63.47M | - | -145.60M | -143.72M | -154.07M | -216.41M |
| EBITDA | - | - | - | -143.45M | -141.57M | -151.47M | -213.76M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -141.95M | -134.24M | -138.20M | -206.69M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -37.18M | -63.41M | - | -141.95M | -134.24M | -138.20M | -206.69M |
| Diluted EPS | - | - | - | -2.60 | -1.77 | -1.01 | -1.34 |
| R&D Expense | 24.52M | 49.27M | 100.07M | 112.50M | 113.76M | 119.45M | 184.70M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 49.90M | 355.95M | - | 285.10M | 297.67M | 350.07M | 277.57M |
| Current Assets | - | - | - | - | 248.10M | 263.86M | 316.46M | 242.19M |
| Cash & Equivalents | 44.17M | 43.93M | 268.56M | - | 140.02M | 225.11M | 49.50M | 162.05M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | 0 | - | - | - | - |
| Total Liabilities | - | 6.37M | 11.67M | - | 53.90M | 47.12M | 56.97M | 65.92M |
| Current Liabilities | - | 4.93M | 10.62M | - | 22.36M | 17.93M | 30.51M | 42.63M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 32.86M | 31.36M | 28.97M | 26.20M |
| Total Equity | -64.20M | -100.45M | 344.28M | - | 231.19M | 250.56M | 293.11M | 211.65M |
| Shares Outstanding | - | - | - | - | 47.72M | 78.37M | 109.38M | 149.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -28.36M | -53.09M | - | -116.31M | -121.14M | -118.01M | -186.36M |
| Investing Cash Flow | -267.00K | -83.16M | - | 58.44M | 70.70M | -218.80M | 190.05M |
| Financing Cash Flow | 28.39M | 360.88M | - | 122.91M | 135.52M | 161.21M | 108.86M |
| Capital Expenditure | -267.00K | -464.00K | - | -6.53M | -193.00K | -15.00K | -137.00K |
| Free Cash Flow | -28.62M | -53.55M | - | -122.83M | -121.33M | -118.02M | -186.49M |
| Net Change in Cash | - | - | - | 65.04M | 85.08M | -175.60M | 112.55M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 37.0% | -18.4% | - | -61.4% | -53.6% | -47.2% | -97.7% |
| ROCE % | -72.3% | -18.4% | - | -55.4% | -51.4% | -48.2% | -92.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 10.30% | 19.52M | $97.01M |
| 2 | Blackrock Inc. | 7.14% | 13.54M | $67.29M |
| 3 | Redmile Group, LLC | 6.26% | 11.87M | $58.99M |
| 4 | State Street Corporation | 5.18% | 9.82M | $48.83M |
| 5 | BVF Inc. | 4.59% | 8.70M | $43.23M |
| 6 | Woodline Partners LP | 3.65% | 6.93M | $34.42M |
| 7 | Vanguard Capital Management LLC | 3.62% | 6.87M | $34.15M |
| 8 | MAK Capital One LLC | 3.09% | 5.86M | $29.14M |
| 9 | Goldman Sachs Group Inc | 3.07% | 5.83M | $28.95M |
| 10 | Siren, L.L.C. | 2.35% | 4.46M | $22.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANNX
Annexon to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 mill…
What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders
In August 2026, Annexon reported a higher second-quarter net loss of US$55.35 million but a lower year-to-date loss of US$99.49 million, while updating investors on its ongoing Phase 3 ARCHER II trial and new open-label extension study for …
Annexon (ANNX), What Is Behind Its Latest Update?
Annexon (ANNX) stock was in focus after the company updated investors on its late stage pipeline, highlighting a dual primary endpoint for the Phase 3 ARCHER II trial and new Guillain Barré syndrome data. See our latest analysis for Annexon…
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts
Annexon, Inc. (NASDAQ:ANNX) shares declined 6.
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to Treat GBS Worldwide,…
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward RegistrationBRISBANE, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platf…
ANNX — Frequently Asked Questions
What is the current share price of Annexon, Inc. (ANNX)?
As of 2026-09-07 16:24 PDT, Annexon, Inc. (ANNX) trades at $4.87 on NasdaqGS. Its 52-week range is $2.05 to $6.96.
What is the market capitalisation of ANNX?
Annexon, Inc. (ANNX) has a market capitalisation of $797.91M on NasdaqGS.
What is the P/E ratio of ANNX?
ANNX trades at a trailing price-to-earnings (P/E) ratio of -4.06. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.30.
What is the return on equity (ROE) of ANNX?
ANNX has a return on equity (ROE) of -87.65%. Its return on capital employed (ROCE) is -92.11%.
Is ANNX a good stock to buy?
This page provides a data-driven analysis of Annexon, Inc. (ANNX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.